Compare Sunrun Inc (RUN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sunrun Inc vs Summit Therapeutics Inc — how do they compare? Sunrun Inc trades at $7.59 (market cap $1.83B), while Summit Therapeutics Inc trades at $17.21 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 7.5× Sunrun Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sunrun Inc for 16 Days and Summit Therapeutics Inc for 16 Days on average.
| RUN | SMMT | |
|---|---|---|
Market Cap | $1.83B | $13.71B |
Volume | 8,672,852 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $21.41 | $26.38 |
52-Week Low | $7.59 | $12.43 |
Typical Hold Time | 16 Days | 16 Days |
Enterprise Value | $16.35B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $7.58, down 0.39% on the day, reflecting a bearish technical trend. The stock shows attractive valuation ratios with a P/E of 5.16 and P/S of 0.59, while recent quarterly earnings have consistently beaten expectations. However, cash flow from operations remains negative, and the company faces headwinds from high borrowing costs impacting the solar sector. Positive developments include a record 580 MW grid dispatch with Tesla and expanded partnerships for distributed computing.
The outlook is mixed: strong analyst support with a $16.33 price target suggests significant upside, but operational cash burn and sector volatility pose risks. Investors should weigh low valuations against execution challenges and macroeconomic pressures affecting solar financing.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
